Jonathon Arnold
Assistant Professor
Pharmacology
University of Sydney
Australia
Biography
Jonathon Arnold is an Associate Professor in the Discipline of Pharmacology. He has over 60 publications which have received > 2000 citations (h-index = 27). His research has attracted national and international funding. In 2005 he conducted research at the Cajal Institute in Madrid, one of the world's premier neuroscience institutes. In 2009 A/Prof Arnold established the Neurobehavioural Laboratory at the Brain and Mind Centre (BMC). In 2015 he was appointed Associate Director of the Lambert Initiative for Cannabinoid Therapeutics which was established as a result of the largest philanthropic donation in the University's history ($33,783,000).
Research Interest
For 20 years Associate Professor Jonathon Arnold has focused on the preclinical pharmacology and therapeutic application of the cannabinoids. His first major discovery was that phytocannabinoids reverse resistance to anticancer drugs. He has also isolated genes that modulate the effects of cannabinoids on the brain. His current work examines the efficacy of cannabinoids in various preclinical models of disease including childhood epilepsy and PTSD.
Publications
-
Todd, S., Zhou, C., Clarke, D., Chohan, T., Bahceci, D., Arnold, J. (2017). Interactions between cannabidiol and (delta)9-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway. European Neuropsychopharmacology, 27(2), 132-145.
-
Brzozowska, N., Smith, K., Zhou, C., Waters, P., Menezes Cavalcante, L., Abelev, S., Kuligowski, M., Clarke, D., Todd, S., Arnold, J. (2017). Genetic deletion of P-glycoprotein alters stress responsivity and increases depression-like behavior, social withdrawal and microglial activation in the hippocampus of female mice. Brain, Behavior, and Immunity, 65, 251-261.
-
Clarke, D., Stuart, J., McGregor, I., Arnold, J. (2017). Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 72, 9-15.
